ADHD Statistics Updated November 2026

Human Written & Fact Checked · Updated

100 ADHD Statistics for 2026

Read the measurement before you compare ADHD statistics. A current diagnosis, a positive symptom screen and a prescription record describe different populations and different stages of care.

This hub brings together primary surveys and original cohort studies, with observation periods kept separate from publication dates. Use the evidence to describe populations and service needs; these statistics do not establish an individual diagnosis or prognosis.

Headline figures

  • US children, 2024: Current ADHD affected 11.7% of US children aged 3–17. (HRSA, Jul 2026)
  • US adults, 2023: An estimated 6.0% of US adults reported a current ADHD diagnosis. (CDC, Oct 2024)
  • US adults with ADHD, 2023: Among adults with ADHD, 55.9% were first diagnosed in adulthood. (CDC, Oct 2024)
  • US adult stimulant users, 2023: Among adults with current ADHD who took stimulants, 71.5% reported difficulty filling prescriptions in the preceding year because medication was unavailable. (CDC, Oct 2024)
  • England adults, 2023/4: In England, 13.9% of adults screened positive; screening does not establish diagnosis. (NHS England, Nov 2025)
  • England adults, 2023/4: A professional ADHD diagnosis was reported by 1.8% of adults. (NHS England, Nov 2025)
  • US children with current ADHD, 2022: Co-occurring disorders affected 77.9% of current cases. (CDC, May 2024)
  • US children with current ADHD, 2022: Among current cases, 30.1% received no ADHD-specific treatment. (CDC, May 2024)
  • MTA longitudinal follow-up: Sustained recovery to study endpoint occurred in 9.1%. (MTA, Aug 2021)
  • MTA longitudinal follow-up: A fluctuating course characterized 63.8%. (MTA, Aug 2021)
  • Swedish observational cohort: Modeled two-year mortality was 39.1 versus 48.1 per 10,000 for medication initiation versus noninitiation. (Karolinska, Mar 2024)
  • UK primary-care records: Female-adult first-prescription incidence increased approximately 20-fold between 2000 and 2018. (UCL, Jul 2023)

Browse ADHD statistics

What does childhood ADHD prevalence measure?

The population and reporting method belong beside the estimate. A parent reporting a current diagnosis answers a different question from a clinician assessing everyone in a population.

How does diagnosis vary by age and sex?

  • Current childhood ADHD prevalence was 14.5% for boys versus 8.8% for girls. (HRSA, Jul 2026)
  • Among ages 3–5, prevalence was 3.7% for boys versus 1.6% for girls. (HRSA, Jul 2026)
  • Among ages 6–11, prevalence was 16.2% for boys versus 8.7% for girls. (HRSA, Jul 2026)
  • Among ages 12–17, prevalence was 17.5% for boys versus 12.0% for girls. (HRSA, Jul 2026)

Parent-reported current ADHD was more common among boys than girls and increased across the age groups in the US survey. The comparisons below concern the same observation year, 2024. These figures describe children whose parents report current ADHD. They do not estimate how many undiagnosed children would meet clinical criteria. The age bands and sex categories are source-defined, and percentages use each respective subgroup as the denominator. An age gradient in this cross-sectional survey does not follow the same children as they grow older.

What did the earlier childhood survey find?

  • Ever-diagnosed ADHD prevalence was 11.4%. (CDC, May 2024)
  • Current ADHD prevalence was 10.5%. (CDC, May 2024)
  • Rural current ADHD prevalence was 11.9%. (CDC, May 2024)
  • Urban current ADHD prevalence was 9.2%. (CDC, May 2024)
  • Southern current ADHD prevalence was 12.1%. (CDC, May 2024)
  • Western current ADHD prevalence was 7.9%. (CDC, May 2024)

The earlier US survey found more ever-diagnosed than currently diagnosed children, with higher current prevalence in rural than urban areas. These observations refer to 2022. Historical observations are retained to show what the earlier study measured. They should not replace the newer headline estimate. Geography describes residence, not a causal explanation for diagnosis; access, recognition and survey response may matter. The ever-diagnosed question retains children whose condition was no longer reported as current. It therefore cannot be used interchangeably with the current-condition question when comparing prevalence between survey years.

How severe and complex are current childhood cases?

  • Among current cases, 41.9% were rated mild. (CDC, May 2024)
  • Moderate severity accounted for 45.3% of current cases. (CDC, May 2024)
  • Severe ADHD accounted for 12.8% of current cases. (CDC, May 2024)
  • Multiple co-occurring disorders affected 51.0%. (CDC, May 2024)
  • Behavioral or conduct problems co-occurred in 44.1%. (CDC, May 2024)
  • Anxiety co-occurred in 39.1%. (CDC, May 2024)
  • Learning disability co-occurred in 36.5%. (CDC, May 2024)
  • Developmental delay co-occurred in 21.7%. (CDC, May 2024)
  • Autism co-occurred in 14.4%. (CDC, May 2024)
  • Severe cases comprised 19.3% below poverty versus 8.9% at or above twice the poverty level. (CDC, May 2024)

Moderate severity was the most common parent-reported category among current cases in the 2022 study. Co-occurring conditions could overlap, so their percentages must not be added. Severity was parent-reported. The poverty comparison concerns the share classified as severe within current ADHD cases, not the prevalence of ADHD among all children in those income groups. These distinctions matter when describing service demand.

What do the data show about care and access?

Diagnosis and access are different milestones. Survey measures of treatment, healthcare use and prescription difficulties help identify where support may fall short.

How do children use healthcare and treatment?

  • Past-year telehealth use was 31.6% among children with current ADHD versus 11.6% without ADHD. (HRSA, Jul 2026)
  • Past-year specialist visits, excluding mental health professionals, occurred for 28.3% of children with current ADHD versus 12.6% without. (HRSA, Jul 2026)
  • Past-year emergency room visits occurred for 22.7% of children with current ADHD versus 16.8% without. (HRSA, Jul 2026)
  • Past-year hospital admissions occurred for 4.7% of children with current ADHD versus 2.9% without. (HRSA, Jul 2026)
  • Unmet healthcare needs affected 8.3% with ADHD versus 3.2% without. (HRSA, Jul 2026)
  • Past-year healthcare costs were sometimes or never reasonable for 31.7% of children with current ADHD versus 26.9% without. (HRSA, Jul 2026)
  • ADHD medication reached 53.6% of current cases. (CDC, May 2024)
  • Past-year ADHD behavioral treatment reached 44.4%. (CDC, May 2024)

Children with current ADHD more often used the listed healthcare services than children without ADHD in 2024. The treatment estimates below instead concern current childhood cases in 2022. Healthcare visits concern any health need, not necessarily ADHD. The comparisons do not establish causation. Treatment categories overlap.

Which care do adults report receiving?

  • At interview, 36.5% of adults with current ADHD received neither medication nor counseling or behavioral treatment. (CDC, Oct 2024)
  • At interview, 35.2% of adults with current ADHD received both medication and counseling or behavioral treatment. (CDC, Oct 2024)
  • At interview, 13.3% of adults with current ADHD received counseling or behavioral treatment alone. (CDC, Oct 2024)
  • At interview, 15.1% of adults with current ADHD received medication alone. (CDC, Oct 2024)
  • An ADHD medication was prescribed during the preceding year to 50.4%. (CDC, Oct 2024)
  • Prescription stimulants were taken in the preceding year by 33.4% of adults with current ADHD. (CDC, Oct 2024)
  • Telehealth for ADHD had ever been used by 46.0% of adults with current ADHD. (CDC, Oct 2024)
  • Diagnosis was entirely by telehealth for 8.9% of adults with current ADHD. (CDC, Oct 2024)
  • Since March 2020, 30.5% of adults with current ADHD used telehealth to obtain ADHD prescriptions. (CDC, Oct 2024)

US adults reported varied treatment combinations in 2023. Current treatment differs from preceding-year use. Prescribing does not establish adherence.

Why is screening different from diagnosis?

Screening results should prompt careful interpretation. A positive ASRS result indicates a need for fuller assessment; it is not a diagnosis.

How does screening relate to recognition and treatment?

  • Positive screening affected 14.9% of women versus 12.4% of men. (NHS England, Nov 2025)
  • ADHD was self-suspected by 5.8% of adults. (NHS England, Nov 2025)
  • Among screen-positive adults, 9.6% reported a professional diagnosis. (NHS England, Nov 2025)
  • Among screen-positive adults, 2.6% were taking ADHD medication. (NHS England, Nov 2025)
  • Among screen-negative adults, 0.5% reported a professional diagnosis. (NHS England, Nov 2025)
  • In the 2014 England survey, 9.7% screened positive for ADHD. (NHS England, Nov 2025)

Positive screening did not consistently coincide with professional diagnosis or medication in England's APMS 2023/4. Screening, self-suspicion and recorded recognition answer different questions. The historical screening observation uses a comparable screening measure. Current sex or gender breakdowns should not be substituted into historical series without checking how the survey recorded them. The findings apply to England's household population. A negative screen also cannot erase a previously reported professional diagnosis. The measures refer to different constructs and observation windows.

Which groups more often screen positive?

  • Age-standardized positive screening was 28.1% with problem debt versus 12.7% without. (NHS England, Nov 2025)
  • Positive screening affected 38.5% with a common mental health condition versus 7.2% without. (NHS England, Nov 2025)
  • Screening-positive prevalence was 25.0% at ages 16–24 versus 3.7% at 75+. (NHS England, Nov 2025)
  • Age-standardized screening positivity among unemployed working-age adults was 29.6%. (NHS England, Nov 2025)
  • Age-standardized screening positivity among employed working-age adults was 14.1%. (NHS England, Nov 2025)
  • Age-standardized screening positivity was 21.2% with limiting physical conditions versus 10.2% without. (NHS England, Nov 2025)

Younger adults and adults reporting debt or limiting physical conditions more often screened positive in England. Employment comparisons also differed after age standardization. Employment comparisons are age-standardized and limited to working-age adults. Health and debt comparisons need their specific denominators. An apparent group difference cannot diagnose a person, and survey associations alone cannot show which circumstance preceded the other.

What can primary-care records tell us?

Clinical records measure recognized and recorded care. They should not be presented as complete counts of everyone living with ADHD.

How frequently were diagnoses recorded?

  • Recorded diagnoses affected 255 per 10,000 boys aged 3–17. (UCL, Jul 2023)
  • Recorded diagnoses affected 67.7 per 10,000 girls aged 3–17. (UCL, Jul 2023)
  • Recorded diagnoses affected 74.3 per 10,000 men aged 18–99. (UCL, Jul 2023)
  • Recorded diagnoses affected 20 per 10,000 women aged 18–99. (UCL, Jul 2023)

Recorded ADHD diagnoses were more frequent among boys than girls and among men than women in the UK primary-care study. The figures below describe 2018 records. This is a historical administrative baseline, not a current population-screening estimate. Records depend on recognition, referral and transfer of information into primary care. The observation should retain its original units instead of being combined with survey percentages. These denominators include the eligible registered population, instead of only patients referred for an ADHD assessment. Comparing referral-clinic records with these population-based rates would change the question being answered.

How frequently were prescriptions recorded?

  • ADHD prescriptions covered 156 per 10,000 boys aged 3–17. (UCL, Jul 2023)
  • ADHD prescriptions covered 36.8 per 10,000 girls aged 3–17. (UCL, Jul 2023)
  • ADHD prescriptions covered 13.3 per 10,000 men aged 18–99. (UCL, Jul 2023)
  • ADHD prescriptions covered 4.5 per 10,000 women aged 18–99. (UCL, Jul 2023)

Ongoing ADHD prescribing was recorded more frequently for boys than girls and for men than women in the UK study. The estimates below describe 2018. Prescribing records do not establish medication adherence or capture every possible source of treatment. The annual prevalence measure differs from the first-prescription incidence trend showed above. Keep the observation year attached when discussing changes in recognition or service capacity. A person can appear in the diagnosis measure without appearing in ongoing prescribing. Those categories should not be subtracted to estimate unmet need without checking clinical circumstances and the study definitions.

What do cohort studies show about health outcomes?

Health-outcome associations deserve context instead of alarm. These studies describe selected diagnosed populations and cannot predict an individual's future.

Was medication initiation linked to mortality?

  • Medication initiation was linked to lower all-cause mortality (HR 0.79, 95% CI 0.70–0.88). (Karolinska, Mar 2024)
  • Unnatural-cause mortality was lower with initiation (HR 0.75, 95% CI 0.66–0.86). (Karolinska, Mar 2024)
  • Natural-cause mortality showed no significant association (HR 0.86, 95% CI 0.71–1.05). (Karolinska, Mar 2024)
  • Within this Swedish incident-diagnosis cohort, 56.7% initiated medication. (Karolinska, Mar 2024)
  • Median diagnosis age in this cohort was 17.4 years. (Karolinska, Mar 2024)
  • There were 632 deaths during two-year follow-up. (Karolinska, Mar 2024)
  • There were 1,402 deaths during five-year follow-up. (Karolinska, Mar 2024)
  • Stimulants accounted for 91.9% of medication initiations. (Karolinska, Mar 2024)
  • Suicide mortality association was not significant (HR 0.88, 95% CI 0.74–1.04). (Karolinska, Mar 2024)

Medication initiation was linked to lower all-cause and unnatural-cause mortality in the Swedish register study. Observational comparisons cannot exclude remaining differences between the treatment groups. The cohort included incident diagnoses from 2007–2018 and follow-up through 2020. Hazard ratios compare rates, not percentage-point differences. Intervals crossing the null indicate a statistically nonsignificant association. Treatment requires clinical assessment.

How did diagnosed UK adults compare with matched peers?

  • Recorded ADHD diagnoses covered 0.32% of this primary-care cohort. (UCL, Jan 2025)
  • Estimated male life expectancy was 73.26 years with diagnosed ADHD versus 80.03 in matched comparisons. (UCL, Jan 2025)
  • Estimated female life expectancy was 75.15 years versus 83.79 in matched comparisons. (UCL, Jan 2025)
  • Male mortality rate ratio was 1.89 (95% CI 1.62–2.19). (UCL, Jan 2025)
  • Female mortality rate ratio was 2.13 (95% CI 1.79–2.53). (UCL, Jan 2025)
  • Median male cohort-entry age was 18.95 years. (UCL, Jan 2025)
  • Median female cohort-entry age was 22.10 years. (UCL, Jan 2025)
  • During follow-up, 0.83% of diagnosed males died versus 0.52% of comparison males. (UCL, Jan 2025)
  • During follow-up, 2.22% of diagnosed females died versus 1.35% of comparison females. (UCL, Jan 2025)

Adults with recorded ADHD had higher observed mortality and lower modeled life expectancy than matched peers in the UK study. The selected diagnosed cohort may not represent undiagnosed people. Records span 2000–2019. Modeled longevity is not an individual prognosis. Cohort-entry ages and deaths describe this selected sample; differences do not establish causation.

How can ADHD change over time?

A single follow-up cannot fully describe a fluctuating course. Longitudinal evidence distinguishes temporary remission, recurrence and sustained recovery.

Does remission always persist?

  • MTA full remission occurred at least once for 31.4%. (MTA, Aug 2021)
  • Among remitters, 59.4% later experienced recurrence. (MTA, Aug 2021)
  • Stable persistence across assessments characterized 10.8%. (MTA, Aug 2021)
  • Stable partial remission characterized 15.6%. (MTA, Aug 2021)
  • Mean interval from remission detection to recurrence was 2.60 years. (MTA, Aug 2021)

No. The MTA follow-up observed recurrence after full remission as well as stable trajectories. Its categories followed explicit symptom, impairment and treatment rules. Full remission required absence of clinically significant impairment and absence of recent ADHD intervention, alongside symptom criteria. That research definition does not imply that people should discontinue useful treatment. Recovery was sustained remission through the study endpoint, not a guarantee about subsequent life. Repeated observations distinguish temporary improvement from sustained change. A favorable result at an assessment is therefore not equivalent to permanent resolution.

How did remission vary across follow-up assessments?

  • Full remission at the two-year assessment was 1.4%. (MTA, Aug 2021)
  • Full remission at the three-year assessment was 2.1%. (MTA, Aug 2021)
  • Full remission at the six-year assessment was 3.3%. (MTA, Aug 2021)
  • Full remission at the eight-year assessment was 6.1%. (MTA, Aug 2021)
  • Full remission at the ten-year assessment was 18.5%. (MTA, Aug 2021)
  • Full remission at the twelve-year assessment was 18.3%. (MTA, Aug 2021)
  • Full remission at the fourteen-year assessment was 18.3%. (MTA, Aug 2021)
  • Full remission at the sixteen-year assessment was 14.6%. (MTA, Aug 2021)

Full remission was more prevalent at later MTA assessments than at the earliest follow-ups, but did not increase at every wave. The time axis measures years after study baseline. Each percentage describes the participants assessed at that wave, not the probability of permanent recovery at a particular birthday. Attrition and the original trial population limit generalization. The sequence is retained as a trajectory, without converting it into a claim that everyone follows the same course.

Glossary

Methodology and sources

Every figure on this page comes from the organisation that produced it: regulators, statistics offices, public bodies, research institutes, and companies reporting their own data or surveys. Each one links to the original report or dataset and carries its release date. Survey results keep their population and fieldwork period, and financial figures keep the measure the producer used. Figures from different producers are not added together or ranked against each other. The page is reviewed monthly and updated when a producer releases newer data.